Cervical intraepithelial neoplasia (CIN) is a disorder in which the cervix grows aberrant cells. Certain kinds of the human papillomavirus (HPV), as well as other environmental variables, can cause it, and it can sometimes lead to cervical cancer precursors. Cervical cancer is uncommon, although cervical intraepithelial neoplasia is not. The bottom section of the uterus that goes into the vaginal canal is known as the cervix. During childbirth, the cervix dilates to allow the foetus to pass through. The aberrant cells in cervical intraepithelial neoplasia aren't malignant. It can, however, grow into precancers or cancer if not monitored or treated in certain circumstances that require therapy. This condition is also termed as cervical dysplasia.
According to the American Cancer Society, roughly 13,800 new instances of invasive cervical cancer were expected to be diagnosed in the United States in 2020, with 4,290 women dying from the disease. Cervical intraepithelial neoplasia is frequently asymptomatic and is found by a standard Pap test. Cervical intraepithelial neoplasia is more common in women under the age of 30, but it can occur at any age. It is strongly linked to sexually transmit human papillomavirus (HPV) infection. Avastin, blemocin, bevacizumb, blenoxane, and others are the various types of drugs used to treat cervical intraepithelial neoplasia and distributed through various channels, including retail pharmacies hospitals pharmacies, and others.
Data Bridge Market Research analyses that the cervical intraepithelial neoplasia drugs market was valued at USD 525.75 million in 2021 and is expected to reach USD 857.13 million by 2029, registering a CAGR of 6.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America dominates the cervical intraepithelial neoplasia drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, surging awareness and government-embedded reimbursement policies will further propel the market's growth rate in this region.
Request a Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cervical-intraepithelial-neoplasia-drugs-market
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of human papillomavirus (HPV) infection in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
Some of the major players operating in the cervical intraepithelial neoplasia drugs market are:
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Novartis AG (Switzerland)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Boehringer Ingelheim International GmbH. (Germany)
AstraZeneca (UK)
Johnson & Johnson Private Limited (US)
Merck & Co., Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Bristol-Myers Squibb Company (US)
Biocon (India)
Amgen Inc. (US)
Eli Lilly and Company (US)
Allergan (Ireland)
Hetero (India)
Abbott (US)
QIAGEN (Netherlands)
Danaher (US)
Related Reports:
Cervical Cancer Drug Market https://www.databridgemarketresearch.com/reports/global-cervical-cancer-drug-market
Robotic Surgery for Cervical Cancer Market https://www.databridgemarketresearch.com/reports/global-robotic-surgery-for-cervical-cancer-market
Cervical Pillows Market https://www.databridgemarketresearch.com/reports/global-cervical-pillows-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475